Sphingosine Kinase-1 Is Overexpressed and Correlates with Hypoxia in Osteosarcoma: Relationship with Clinicopathological Parameters.

FTY720 GLUT-1 HIF S1P1 fingolimod osteosarcoma sphingosine kinase

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
19 Jan 2022
Historique:
received: 08 12 2021
revised: 14 01 2022
accepted: 16 01 2022
entrez: 15 2 2022
pubmed: 16 2 2022
medline: 16 2 2022
Statut: epublish

Résumé

The Sphingosine kinase-1/Sphingosine 1-Phosphate (SphK1/S1P) signaling pathway is overexpressed in various cancers, and is instrumental for the adaptation to hypoxia in a number of solid tumor models, but no data are available in osteosarcoma. Here we report that SphK1 and the S1P

Identifiants

pubmed: 35158767
pii: cancers14030499
doi: 10.3390/cancers14030499
pmc: PMC8833796
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Ligue Nationale contre le Cancer
ID : NA

Références

Crit Rev Oncol Hematol. 2020 Dec;156:103126
pubmed: 33113487
J Biol Chem. 2011 May 27;286(21):18633-40
pubmed: 21464128
Springerplus. 2016 Aug 19;5(1):1370
pubmed: 27606158
N Engl J Med. 2010 Feb 4;362(5):402-15
pubmed: 20089954
Vet Comp Oncol. 2008 Jun;6(2):133-40
pubmed: 19178673
Cancer Lett. 2015 Feb 1;357(1):254-264
pubmed: 25444927
PLoS One. 2019 Mar 7;14(3):e0213203
pubmed: 30845158
Clin Cancer Res. 2010 Dec 15;16(24):5928-35
pubmed: 20962028
J Clin Oncol. 2008 Feb 1;26(4):633-8
pubmed: 18235123
J Exp Clin Cancer Res. 2015 Feb 28;34:22
pubmed: 25884381
Cancer Metastasis Rev. 2007 Jun;26(2):225-39
pubmed: 17440684
Mol Cancer Ther. 2012 Sep;11(9):1841-51
pubmed: 22784711
Cancers (Basel). 2021 Jan 15;13(2):
pubmed: 33467731
J Cell Physiol. 2011 Jun;226(6):1425-32
pubmed: 21321933
Cancer Res. 2002 Mar 1;62(5):1410-9
pubmed: 11888913
Int J Biol Markers. 2016 Jul 30;31(3):e229-34
pubmed: 27312586
Pediatr Blood Cancer. 2013 Sep;60(9):1418-23
pubmed: 23704073
Cancer Res. 2003 Sep 15;63(18):5962-9
pubmed: 14522923
Lancet Oncol. 2016 Jul;17(7):896-906
pubmed: 27237614
Pathologe. 1983 May;4(3):135-41
pubmed: 6576329
FASEB J. 2004 Mar;18(3):551-3
pubmed: 14715694
J Clin Oncol. 2015 Jul 10;33(20):2279-87
pubmed: 26033801
Cell Rep. 2014 Apr 10;7(1):104-12
pubmed: 24703847
Eur J Cancer. 2010 Dec;46(18):3417-24
pubmed: 20970322
PLoS One. 2014 Mar 11;9(3):e90518
pubmed: 24618817
Nat Rev Drug Discov. 2013 Sep;12(9):688-702
pubmed: 23954895
Adv Cancer Res. 2013;117:117-41
pubmed: 23290779
PLoS One. 2013 Jun 13;8(6):e65304
pubmed: 23785417
Lancet Oncol. 2016 Aug;17(8):1070-1080
pubmed: 27324280
Cell Death Differ. 2001 Feb;8(2):162-71
pubmed: 11313718
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Aug;106(2):254-7
pubmed: 18554951
Jpn J Clin Oncol. 2007 Feb;37(2):127-34
pubmed: 17237146
EMBO J. 2003 Oct 15;22(20):5491-500
pubmed: 14532121
Int J Clin Oncol. 2015 Dec;20(6):1233-43
pubmed: 26077139
Nat Rev Cancer. 2002 Jan;2(1):38-47
pubmed: 11902584
Onco Targets Ther. 2021 Feb 11;14:995-1002
pubmed: 33603404
Cancer Res. 2009 May 1;69(9):3723-6
pubmed: 19383898
Nat Rev Cancer. 2014 Nov;14(11):722-35
pubmed: 25319867
BMC Cancer. 2010 Jul 16;10:372
pubmed: 20637078
Cancers (Basel). 2020 Dec 30;13(1):
pubmed: 33396725
Clin Orthop Relat Res. 2015 Jan;473(1):305-10
pubmed: 25193692
Oncogenesis. 2016 Mar 14;5:e209
pubmed: 26974204
PLoS One. 2014 Feb 27;9(2):e90362
pubmed: 24587339
Oncotarget. 2015 May 30;6(15):13803-21
pubmed: 25915662
Cell. 2012 Feb 3;148(3):399-408
pubmed: 22304911
Clin Cancer Res. 2013 Jan 1;19(1):138-47
pubmed: 23166225
Cancer Res. 2008 Oct 15;68(20):8635-42
pubmed: 18922940
Oncol Lett. 2012 May;3(5):1011-1016
pubmed: 22783382
Clin Orthop Relat Res. 2008 Sep;466(9):2052-9
pubmed: 18528739
Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):E5564-73
pubmed: 25512523
J Bone Oncol. 2016 Jan 28;5(1):22-9
pubmed: 26998423
Diagn Pathol. 2014 Nov 29;9:221
pubmed: 25432701
Methods Mol Biol. 2012;874:1-20
pubmed: 22528435
Mol Cancer Ther. 2016 Oct;15(10):2465-2474
pubmed: 27507852
Ann Oncol. 2016 Apr;27(4):738-44
pubmed: 26787232
J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54
pubmed: 17895480
Onco Targets Ther. 2016 Mar 14;9:1477-87
pubmed: 27042116
Clin Cancer Res. 2000 Feb;6(2):572-7
pubmed: 10690541
Histopathology. 2015 Sep;67(3):368-77
pubmed: 25641082
Pediatr Blood Cancer. 2012 Dec 15;59(7):1215-22
pubmed: 22544557
J Biochem Mol Toxicol. 2007;21(5):273-9
pubmed: 17912702
Cancer Res. 2010 Nov 1;70(21):8651-61
pubmed: 20959468
Cancer Res. 2006 Jan 1;66(1):221-31
pubmed: 16397235
N Engl J Med. 2010 Feb 4;362(5):387-401
pubmed: 20089952
Oncol Lett. 2019 Aug;18(2):1259-1266
pubmed: 31423186
Lancet Oncol. 2016 Oct;17(10):1396-1408
pubmed: 27569442
Chin J Cancer Res. 2017 Oct;29(5):447-454
pubmed: 29142464
Curr Mol Pharmacol. 2010 Jun;3(2):53-65
pubmed: 20302564

Auteurs

Anne Gomez-Brouchet (A)

CNRS, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France.
Université de Toulouse, UPS, 31400 Toulouse, France.
Département d'Anatomie et Cytologie Pathologies, Institut Universitaire du Cancer de Toulouse-Oncopôle (IUCT-O), 31059 Toulouse, France.
Cancer Biobank, Institut Universitaire du Cancer de Toulouse-Oncopôle (IUCT-O), 31059 Toulouse, France.

Claire Illac (C)

CNRS, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France.
Université de Toulouse, UPS, 31400 Toulouse, France.
Département d'Anatomie et Cytologie Pathologies, Institut Universitaire du Cancer de Toulouse-Oncopôle (IUCT-O), 31059 Toulouse, France.

Adeline Ledoux (A)

CNRS, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France.
Université de Toulouse, UPS, 31400 Toulouse, France.

Pierre-Yves Fortin (PY)

CNRS, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France.
Université de Toulouse, UPS, 31400 Toulouse, France.

Sandra de Barros (S)

Service de Pharmacologie Clinique, Hôpitaux de Toulouse, 31300 Toulouse, France.

Clémentine Vabre (C)

Service de Pharmacologie Clinique, Hôpitaux de Toulouse, 31300 Toulouse, France.

Fabien Despas (F)

Service de Pharmacologie Clinique, Hôpitaux de Toulouse, 31300 Toulouse, France.

Sophie Peries (S)

Service de Pharmacologie Clinique, Hôpitaux de Toulouse, 31300 Toulouse, France.

Christelle Casaroli (C)

Cancer Biobank, Institut Universitaire du Cancer de Toulouse-Oncopôle (IUCT-O), 31059 Toulouse, France.

Corinne Bouvier (C)

Department of Pathology, CHU la Timone, 13005 Marseille, France.

Sébastien Aubert (S)

Department of Pathology, CHRU de Lille, 50037 Lille, France.

Gonzague de Pinieux (G)

Department of Pathology, CHU de Tours, 37044 Tours, France.

Frédérique Larousserie (F)

Department of Pathology, AP-HP, Hôpital Cochin, Universiteé Paris Descartes, 75014 Paris, France.

Louise Galmiche (L)

Centre Hospitalier Universitaire de Nantes Hôtel Dieu, 44000 Nantes, France.

Franck Talmont (F)

CNRS, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France.
Université de Toulouse, UPS, 31400 Toulouse, France.

Stuart Pitson (S)

Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA 5000, Australia.

Marie-Lise Maddelein (ML)

CNRS, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France.
Université de Toulouse, UPS, 31400 Toulouse, France.

Olivier Cuvillier (O)

CNRS, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France.
Université de Toulouse, UPS, 31400 Toulouse, France.

Classifications MeSH